Literature DB >> 33911107

Evaluation of digital dispense-assisted broth microdilution antimicrobial susceptibility testing for Pseudomonas aeruginosa isolates.

Shawn T Clark1,2, Patrick J Stapleton3, Pauline W Wang4, Yvonne C W Yau5,3, Valerie J Waters5,6, David M Hwang5,7, David S Guttman8,4.   

Abstract

Antimicrobial susceptibility testing (AST) is essential for detecting resistance in Pseudomonas aeruginosa and other bacterial pathogens. Here we evaluated the performance of broth microdilution (BMD) panels created using a semi-automated liquid handler, the D300e Digital Dispenser (Tecan Group Ltd., CH) that relies on inkjet printing technology. Microtitre panels (96-well) containing nine twofold dilutions of 12 antimicrobials from five classes (β-lactams, β-lactam/β-lactamase inhibitors, aminoglycosides, fluoroquinolones, polymyxins) were prepared in parallel using the D300e Digital Dispenser and standard methods described by CLSI/ISO. To assess performance, panels were challenged with three well characterized quality control organisms and 100 clinical P. aeruginosa isolates. Traditional agreement and error measures were used for evaluation. Essential (EA) and categorical (CA) agreements were 92.7% and 98.0% respectively for P. aeruginosa isolates with evaluable on-scale results. The majority of minor errors that fell outside acceptable EA parameters (≥ ± 1 dilution, 1.9%) were seen with aztreonam (5%) and ceftazidime (4%), however all antimicrobials displayed acceptable performance in this situation. Differences in MIC were often log2 dilution lower for D300e dispensed panels. Major and very major errors were noted for aztreonam (2.6%) and cefepime (1.7%) respectively. The variable performance of D300e panels suggests that further testing is required to confirm their diagnostic utility for P. aeruginosa.

Entities:  

Year:  2021        PMID: 33911107     DOI: 10.1038/s41598-021-88423-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  4 in total

Review 1.  Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories.

Authors:  Romney M Humphries; April N Abbott; Janet A Hindler
Journal:  J Clin Microbiol       Date:  2019-05-24       Impact factor: 5.948

Review 2.  CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests.

Authors:  Romney M Humphries; Jane Ambler; Stephanie L Mitchell; Mariana Castanheira; Tanis Dingle; Janet A Hindler; Laura Koeth; Katherine Sei
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

3.  Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Complex.

Authors:  Sergio García-Fernández; Yohann Bala; Tom Armstrong; María García-Castillo; C A Burnham; Meghan A Wallace; Dwight Hardy; Gilles Zambardi; Rafael Cantón
Journal:  J Clin Microbiol       Date:  2020-01-28       Impact factor: 5.948

4.  Validation of Aztreonam-Avibactam Susceptibility Testing Using Digitally Dispensed Custom Panels.

Authors:  Eric Ransom; Amelia Bhatnagar; Jean B Patel; Maria-Jose Machado; Sandra Boyd; Natashia Reese; Joseph D Lutgring; David Lonsway; Karen Anderson; Allison C Brown; Christopher A Elkins; J Kamile Rasheed; Maria Karlsson
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.